SCHEMBL29930822

SCHEMBL29930822

Fc1ccc(F)c(-c2cnc3[nH]ncc3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 3/20 0.46
PIK3CA P42336 2/20 0.42
AKT1 P31749 1/20 0.42
TGFBR1 P36897 3/20 0.41
ABL1 P00519 3/20 0.41
PIK3C3 Q8NEB9 3/20 0.41
BRAF P15056 2/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C8 P10632 1/20 0.39
CDC7 O00311 2/20 0.39
PLK4 O00444 1/20 0.38
CHEK1 O14757 1/20 0.38
PDPK1 O15530 1/20 0.38
DYRK3 O43781 1/20 0.38
JAK2 O60674 1/20 0.38
ROCK2 O75116 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
NTRK1 P04629 1/20 0.38
INSR P06213 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13854150 0.79 NUDT1 (0.56) PIK3CAABL1PLK4CHEK1PDPK1
SCHEMBL15638845 0.76 TGFBR1 (0.57) TRPA1PIK3CAAKT1TGFBR1PIK3C3
SCHEMBL15639894 0.74 TGFBR1 (0.52) TRPA1PIK3CAAKT1TGFBR1PIK3C3
SCHEMBL15640079 0.74 TGFBR1 (0.52) TRPA1PIK3CAAKT1TGFBR1PIK3C3
SCHEMBL14977221 0.73 NAMPT (0.40) PIK3CAAKT1PIK3C3BRAFCDC7
SCHEMBL23098906 0.71 PIK3CA (0.49) PIK3CAAKT1ABL1PIK3C3PLK4
SCHEMBL15639399 0.71 TGFBR1 (0.54) TRPA1PIK3CAAKT1TGFBR1PIK3C3
SCHEMBL29930718 0.70 AXL (0.61) PIK3CAAKT1ABL1PIK3C3PLK4
SCHEMBL29730584 0.70 SGK1 (0.58) BRAFSGK1
SCHEMBL14555479 0.70 PIK3CA (0.41) TRPA1PIK3CAAKT1ABL1PIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022235097-A1 PHARMACEUTICAL COMPOSITION CONTAINING NOVEL PYRAZOLO[3,4-B]PYRIDINE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE INCLUDING OBESITY AND DIABETES MELLITUS OR NONALCOHOLIC STEATOHEPATITIS 한국화학연구원 2022-11-10 WO disclosed